Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Safety and Efficacy Study of Safusidenib in Participants With IDH1-Mutant Glioma Who Discontinued Vorasidenib Treatment Due to Progressive Disease

8 november 2026 uppdaterad av: Nuvation Bio Inc.

A Phase 2, Multicenter, Clinical Study to Evaluate the Efficacy and Safety of Safusidenib Erbumine in Participants With Isocitrate Dehydrogenase 1 (IDH1)-Mutant Glioma Who Discontinued Vorasidenib Treatment Due to Progressive Disease

This study will include up to 40 participants with Grade 2 or Grade 3 IDH1-mutant glioma who have undergone surgery and received vorasidenib as their only treatment, experienced radiographic disease progression on vorasidenib (confirmed by Blinded Independent Central Review [BICR] per modified Response Assessment in Neuro-Oncology [RANO] 2.0), and are not in need of immediate chemotherapy or radiotherapy.

Studieöversikt

Studietyp

Interventionell

Inskrivning (Beräknad)

40

Fas

  • Fas 2

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studiekontakt

Studieorter

    • California
      • Los Angeles, California, Förenta staterna, 90095
        • Har inte rekryterat ännu
        • University of California, Los Angeles
        • Huvudutredare:
          • Robert Chong, MD
        • Kontakt:
      • San Francisco, California, Förenta staterna, 94143
        • Har inte rekryterat ännu
        • University of California, San Francisco
        • Huvudutredare:
          • John De Groot, MD
        • Kontakt:
    • Connecticut
      • New Haven, Connecticut, Förenta staterna, 06510
    • Florida
      • Miami, Florida, Förenta staterna, 33136
        • Har inte rekryterat ännu
        • University of Miami Health
        • Kontakt:
        • Huvudutredare:
          • Juan Blaquier, MD
    • Indiana
      • Indianapolis, Indiana, Förenta staterna, 46202
        • Rekrytering
        • Indiana University
        • Huvudutredare:
          • Kathryn Nevel, MD
        • Kontakt:
          • NeuroOncology Clinical Trials
          • Telefonnummer: 3179634823
          • E-post: neuroct@iu.edu
    • Louisiana
      • New Orleans, Louisiana, Förenta staterna, 70112
        • Har inte rekryterat ännu
        • LSU LCMC Health Cancer Center
        • Huvudutredare:
          • Yazmin Odia, MD
        • Kontakt:
    • Massachusetts
      • Boston, Massachusetts, Förenta staterna, 02214
        • Har inte rekryterat ännu
        • Massachusetts General Hospital
        • Kontakt:
        • Huvudutredare:
          • Vihang Nakhate, MD
    • New Jersey
      • New Brunswick, New Jersey, Förenta staterna, 08901
        • Har inte rekryterat ännu
        • Rutgers Cancer Institute
        • Huvudutredare:
          • Morana Vojnic, MD
        • Kontakt:
    • New York
      • New York, New York, Förenta staterna, 10016
      • New York, New York, Förenta staterna, 10032
        • Har inte rekryterat ännu
        • Columbia University Medical Center
        • Huvudutredare:
          • Andrew Lassman, MD
        • Kontakt:
    • Ohio
      • Cleveland, Ohio, Förenta staterna, 44106
        • Har inte rekryterat ännu
        • Cleveland Clinic
        • Huvudutredare:
          • Mina Lobbous, MD
        • Kontakt:
      • Columbus, Ohio, Förenta staterna, 43210
        • Har inte rekryterat ännu
        • The Ohio State University Comprehensive Cancer Center
        • Kontakt:
        • Huvudutredare:
          • Pierre Giglio, MD

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

18 år och äldre (Vuxen, Äldre vuxen)

Tar emot friska volontärer

Nej

Kön som är behöriga för studier

Allt

Beskrivning

Key Inclusion Criteria:

  • Histologically confirmed Grade 2 or 3 IDH-mutant astrocytoma or IDH-mutant and 1p19q co-deleted oligodendroglioma, according to WHO CNS 2021 criteria
  • IDH1 mutation (e.g., R132H/C/G/S/L) based on immunohistochemistry (IHC) (R132H only), PCR, or next generation sequencing (NGS).
  • Have had at least 1 prior surgery for glioma (biopsy, sub-total resection, or gross total resection).
  • Measurable disease per modified RANO 2.0 confirmed by BICR during Screening.
  • Previously treated with vorasidenib and experienced radiographic disease progression during treatment and are not in need of immediate chemotherapy or radiotherapy in the opinion of the Investigator. Disease progression must be confirmed by BICR using modified RANO 2.0.
  • Adequate hematologic and organ function
  • Expected survival of ≥12 months

Key Exclusion Criteria:

  • Any prior anticancer therapy other than surgery (biopsy, sub-total, or gross total resection) and vorasidenib for treatment of glioma.
  • Discontinued vorasidenib for toxicity or any reason other than radiographic disease progression
  • Prior treatment with anti-angiogenic agents such as Avastin (bevacizumab) or investigational agents for glioma.
  • Brainstem or spinal cord involvement either as primary location, site of multifocal involvement, or by significant tumor extension.
  • Significant functional or neurocognitive deficits, including uncontrolled seizures
  • Evidence of leptomeningeal disease.
  • Use of therapeutic doses of steroids for signs/symptoms of glioma. Participants taking physiologic doses (defined as equivalent of <1.5 mg of dexamethasone equivalent) for medical conditions not related to glioma will be permitted.

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Behandling
  • Tilldelning: N/A
  • Interventionsmodell: Enskild gruppuppgift
  • Maskning: Ingen (Open Label)

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Experimentell: Safusidenib

Safusidenib 250 mg BID

Safusidenib administered twice daily as a single agent orally on Days 1 to 28 of a 28-day cycle. Participants may continue treatment until disease progression or another reason for discontinuation occurs.

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Objective Response Rate (ORR) per modified Response Assessment in Neuro-Oncology (RANO) 2.0 assessed by Blinded Independent Central Review (BICR)
Tidsram: From the date of first dose of study drug until the date of first documented disease progression, approximately 18 months

ORR defined as the proportion of participants with the confirmed best overall response of Complete Response (CR), Partial Response (PR) or Minor Response (MR) per modified RANO 2.0, assessed by BICR

From the date of first dose of study drug until the date of first documented disease progression, approximately 18 months

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
ORR per modified RANO 2.0 assessed by Investigator
Tidsram: From the date of first dose of study drug until the date of first documented disease progression, approximately 18 months

ORR defined as the proportion of participants with the confirmed best overall response of CR, PR or MR per modified RANO 2.0, assessed by the Investigator

From the date of first dose of study drug until the date of first documented disease progression, approximately 18 months
Volumetric Tumor Growth Rate (TGR) by BICR
Tidsram: From historical scans through the final scan in the study, approximately 18 months

TGR defined as the percentage change in tumor volume by unit of time, assessed by BICR

From historical scans through the final scan in the study, approximately 18 months
Duration of Response (DOR) per modified RANO 2.0 assessed by BICR and by Investigator
Tidsram: From the date of first dose of study drug until the date of first documented disease progression, approximately 18 months

DOR, time from the first documentation of objective response (CR, PR, or MR) to the date of the first occurrence of radiographic disease progression per modified RANO 2.0 assessed by BICR and by the Investigator or death from any cause, whichever occurs earlier.

From the date of first dose of study drug until the date of first documented disease progression, approximately 18 months
Time to Next Intervention (TTNI)
Tidsram: From the date of first dose of study drug until the date of the start of another anticancer treatment or date of death, approximately 18 months

TTNI, defined as the time from the first dose of study drug to the initiation of first subsequent anticancer therapy or death from any cause, whichever occurs earlier

From the date of first dose of study drug until the date of the start of another anticancer treatment or date of death, approximately 18 months
Progression Free Survival (PFS) per modified RANO 2.0 assessed by BICR and by Investigator
Tidsram: From the date of first dose of study drug until the date of first documented disease progression, approximately 18 months

PFS, defined as the time from the first dose of study drug to the date of the first occurrence of radiographic disease progression per modified RANO 2.0 assessed by BICR and by the Investigator or death from any cause, whichever occurs earlier.

From the date of first dose of study drug until the date of first documented disease progression, approximately 18 months
Time to Response (TTR) per modified RANO 2.0 assessed by BICR and by Investigator
Tidsram: From the date of first dose of study drug to the first documentation of objective response (CR, PR, or MR), approximately 18 months

TTR, defined as the time from the first dose of study drug to the first documentation of objective response (CR, PR, or MR) per modified RANO 2.0, assessed by BICR and by the Investigator

From the date of first dose of study drug to the first documentation of objective response (CR, PR, or MR), approximately 18 months
Overall Survival (OS)
Tidsram: From the date of first dose of study drug until the date of death, approximately 18 months

OS, defined as the time from the first dose of study drug to death from any cause.

From the date of first dose of study drug until the date of death, approximately 18 months
Safety and tolerability
Tidsram: From the date of first dose of study drug until 30 days after the date of the last dose of study drug, approximately 18 months

The safety and tolerability of safusidenib evaluated based on AEs graded by NCI-CTCAE version 5.0, laboratory abnormalities as graded by NCI-CTCAE version 5.0, vital signs, physical examinations, and ECGs

From the date of first dose of study drug until 30 days after the date of the last dose of study drug, approximately 18 months
Seizure Activity
Tidsram: From the date of first dose of study drug until the date of first documented disease progression, approximately 18 months

Evaluate seizure frequencies and severity including type of seizure, seizure-related AEs, and changes in anti-epileptic medications in participants receiving safusidenib

From the date of first dose of study drug until the date of first documented disease progression, approximately 18 months

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Beräknad)

1 mars 2027

Primärt slutförande (Beräknad)

1 september 2030

Avslutad studie (Beräknad)

1 mars 2032

Studieregistreringsdatum

Först inskickad

9 juli 2026

Först inskickad som uppfyllde QC-kriterierna

9 juli 2026

Första postat (Faktisk)

14 juli 2026

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

10 november 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

8 november 2026

Senast verifierad

1 november 2026

Mer information

Termer relaterade till denna studie

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

NEJ

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Ja

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera